ACXP logo

ACXP Acurx Pharmaceuticals, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$1.04
+0.01 (+0.97%)

Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostri…

Market Cap: $6.30Mwww.acurxpharma.com

Price

No data yet.

Social Signal Score

54
5d
—
30d
50
2 mentions
—
60d
57
3 mentions
—
90d
57
3 mentions
—
news: 3

Analyst Ratings

3 analysts
Buyconsensus
Strong Buy 0Buy 3Hold 0Sell 0Strong Sell 0

Revenue

$0.00
$0.00
Mar 2020Sep 2026

Analyst Estimates

FY2025
$-6.05
$-6.05–$-6.05
1 analysts
FY2026
$-1.92
$-1.92–$-1.92
1 analysts
FY2027
$-1.56
$-1.56–$-1.56
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
David Luci
Sector
Healthcare
Industry
Biotechnology
Employees
4
Beta
-2.08
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-11.57
www.acurxpharma.com